Molecular profiling of the patient’s tumor also identified a novel HER2 mutation affecting the protein tyrosine kinase domain and a CHEK2 mutation previously identified as a cancer susceptibility gene in the Finnish population (38, 39). This evidence concerns the gene CHEK2 and neoplasm.